These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 30259975)

  • 1. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel UCHL
    Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
    Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
    BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    Zhang J; Yang C; Tang P; Chen J; Zhang D; Li Y; Yang G; Liu Y; Zhang Y; Wang Y; Liu J; Ouyang L
    J Med Chem; 2022 May; 65(9):6803-6825. PubMed ID: 35442700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    Domagala P; Hybiak J; Cybulski C; Lubinski J
    Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
    Shi Y; Jin J; Wang X; Ji W; Guan X
    Neoplasia; 2019 Jun; 21(6):533-544. PubMed ID: 31029033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
    Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    Li Y; Wang Y; Zhang W; Wang X; Chen L; Wang S
    Sci Rep; 2021 Feb; 11(1):4774. PubMed ID: 33637776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer.
    Orhan E; Velazquez C; Tabet I; Fenou L; Rodier G; Orsetti B; Jacot W; Sardet C; Theillet C
    Cancer Lett; 2024 May; 589():216820. PubMed ID: 38574883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.